The Future of Cancer Treatment: Exploring the Advancements and Challenges in the Cancer Treatment Drugs Market | UnivDatos Market Insights

0
69

Cancer is a disease that is caused by the uncontrolled growth of abnormal cells in the body. It is one of the leading causes of death worldwide, with millions of people being diagnosed with the disease each year. Some of the major factors contributing to cancer cases include tobacco use, exposure to harmful gases, poor diet, physical inability, infectious agents, and others.  

Request Sample PDF here @ https://univdatos.com/report/cancer-treatment-drugs-market/get-a-free-sample-form.php?product_id=36487

The surge in the incidence of cancer has surged the demand for cancer treatment drugs in the past few years. According to World Health Organization, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020 globally. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers.

 

Figure 1: Worldwide Cancer Incidence’2020

The development of cancer therapies has been an active area of research for many years, resulting in a range of treatment options that can be used to manage and treat cancer. These therapies include surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, and hormone therapy, among others. Targeted therapy is a type of cancer treatment that uses drugs or other substances to identify and attack specific cancer cells without harming normal cells. Unlike chemotherapy, which attacks all rapidly dividing cells, including healthy ones, targeted therapy is designed to specifically target cancer cells and spare healthy cells. Currently, the majority of research is being focused on the development of new targeted therapies.

Apart from targeted therapy, immunotherapy has also gained considerable momentum among pharmaceutical giants. Immunotherapy is a type of cancer treatment that harnesses the power of the immune system to recognize approaches including therapeutic antibodies, immune checkpoint inhibitors, vaccines, chimeric antigen receptor T-cell therapy, and others which have shown promising responses in the management of several cancers.

Ask for Customization @ https://univdatos.com/report/cancer-treatment-drugs-market/get-a-free-sample-form.php?product_id=36487

The encouraging response has propelled further research and development activities among pharmaceutical giants design more efficient and targeted cancer drugs. The major companies in cancer research including Sanofi, Pfizer, Amgen, Roche, and others have actively invested in cancer research. For instance, in July 2021, Amgen acquired  Teneobio, a privately held, clinical-stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies. The acquisition includes Teneobio's proprietary bispecific and multispecific antibody technologies, which will enable significant acceleration and efficiency in the discovery and development of new molecules that have the potential to treat cancer and other chronic diseases.

                Figure 2: Cancer Treatment drugs approval by U.S. FDA, 2016-2021

 

Get more information , Please Visit us : https://univdatos.com/report/cancer-treatment-drugs-market/

 

RECENT FDA DRUG APPROVALS

DATE

Drug name

COMPANY

INDICATION

1/27/2023

Jaypirca (pirtobrutinib)

Lilly

adult patients with relapsed or refractory mantle cel lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.

1/19/2023

Tukysa (tucatinib)               

Seagen Inc.

In combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive, unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy

12/22/2022

Lunsumio (mosunetuzumab-axgb)

Genentech, Inc.

Adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

12/12/2022

Krazati (adagrasib)

Mirati Therapeutics, Inc.

Adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

11/14/2022

Elahere (mirvetuximab soravtansine-gynx)

ImmunoGen Inc.,

Adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test

10/25/2022               

Tecvayli (teclistamab-cqyv)

Janssen Global Services, LLC,

Adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody

9/30/2022

Lytgobi (futibatinib)

TAIHO ONCOLOGY, INC.

Adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements

 

CONCLUSION

The demand for cancer treatment drugs is growing at high rates in the past few years, with several big players adopting strategic alliances with emerging small start-ups with an aim to launch novel cancer therapies. Further, investments in cancer research have also increased over the past few years and so are the adoption rate. Patients in the US are the highest adopter of novel cancer therapies followed by developed European countries including the UK, Denmark, and France. Developing countries such as India, China, and other Middle East countries have witnessed increased adoption of cancer treatment drugs over the past few years, but at a slow pace, however, the demand for cancer therapies is expected to increase by 2022, owing to the surge in the prevalence of cancer and rising awareness among the individuals regarding the availability of cancer treatment drugs. Contact Universal Data Solutions, a rapidly growing dynamic market research firm led by a core of dedicated professionals for further information. According to the Universal Data Solutions analysis, the development of advanced technologies would massively transform the global scenario of cancer treatment drugs and as per their “Cancer Treatment Drugs Market” report, the global market was valued at USD 150 billion in 2021, growing at a CAGR of 10% during the forecast period from 2022 - 2028 to reach USD XX billion by 2028.

Zoeken
Categorieën
Read More
Shopping
Artisanal Mastery: Handmade Jewelry for Distinctive Style
Artisanal Mastery is the birth of skilled version of Art in unexpectedly heart warming versions...
By Nova Martin 2023-08-28 11:26:52 0 242
Other
Fly cincinnati newark with allegiant airlines
Allegiant Airlines is a low-cost carrier that operates flights from Cincinnati/Northern Kentucky...
By Booking Trolley 2023-04-04 00:02:52 0 85
Other
Bunker Fuel Market, Size, Key Drivers,Opportunities 2032
The bunker fuel market is a significant sector within the energy industry that focuses on the...
By Maxjoy Joy 2023-05-30 05:05:55 0 24
Theater
Uranium Growth, Revenue Share Analysis, Company Profiles, And Forecast To 2030
Reports and Data estimates the global Uranium competitive landscape is highly fragmented with...
By Tom Hardy 2022-11-07 10:14:48 0 24
Other
Automotive Alloys Market Segmentation by Alloy Type: Aluminum, Magnesium, Steel, and Others
Automotive Alloys Market Scope Strict government regulations for environmental safety are also...
By Devanand Patil 2023-03-22 11:30:11 0 39